Why Is McKesson Stock Trading Lower Today? - McKesson (NYSE:MCK)
McKesson beats expectations with Q3 2024 sales of $80.9 billion, up 15%. U.S. Pharmaceutical Segment thrives, adjusted EPS at $7.74, exceeding consensus.
Allison Jacobsen Mckesson Corporation Eric Coldwell Prescription Technology Solutions Prescription Technology Solutions Segment Rite Aid
Source: benzinga.com